Insmed (INSM) Amortizatization of Intangibles (2013 - 2026)
Insmed (INSM) posted Amortizatization of Intangibles of $678000.0 for Q2 2026, little changed on a QoQ basis from $678000.0 in Q1 2026, and little changed year-over-year from $678000.0 in Q2 2025.
Powered by 
Analysis
Insmed (INSM) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Insmed has reported Amortizatization of Intangibles for 14 years, with the latest figure at $678000.0 in Q2 2026.
- On a quarterly basis, Amortizatization of Intangibles changed 0.0% year-over-year to $678000.0 in Q2 2026; TTM through Jun 2026 was $2.7 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.7 million, changed 0.0% from the prior year.
- Amortizatization of Intangibles was $678000.0 for Q2 2026 at Insmed, roughly flat from $678000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $729000.0 in Q1 2022, with the low at $114000.0 in Q4 2022.
- Average Amortizatization of Intangibles over 5 years is $636222.2, with a median of $678000.0 recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles sank 99.6% in 2022, then soared 494.74% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at $114000.0 in 2022, then jumped by 494.74% to $678000.0 in 2023, then changed by 0.0% to $678000.0 in 2024, then changed by 0.0% to $678000.0 in 2025, then changed by 0.0% to $678000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $678000.0 (Q2 2026), $678000.0 (Q1 2026), and $678000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 678,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 678,000.00 |
| Mar 31, 2026 | 678,000.00 |
| Dec 31, 2025 | 678,000.00 |
| Sep 30, 2025 | 678,000.00 |
| Jun 30, 2025 | 678,000.00 |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 678,000.00 |
| Sep 30, 2024 | 678,000.00 |
| Jun 30, 2024 | 678,000.00 |
| Mar 31, 2024 | 678,000.00 |
| Dec 31, 2023 | 678,000.00 |
| Sep 30, 2023 | 678,000.00 |
| Jun 30, 2023 | 678,000.00 |
| Mar 31, 2023 | 678,000.00 |
| Dec 31, 2022 | 114,000.00 |
| Sep 30, 2022 | 481,000.00 |
| Jun 30, 2022 | 636,000.00 |
| Mar 31, 2022 | 729,000.00 |
| Dec 31, 2021 | 28.34 Mn |
| Sep 30, 2021 | 8.32 Mn |